Printer Friendly

Innate Pharma SA concludes target enrollment of 150 Acute Myeloid Leukemia patients in EffiKIR trial.

M2 EQUITYBITES-July 25, 2014-Innate Pharma SA concludes target enrollment of 150 Acute Myeloid Leukemia patients in EffiKIR trial

(C)2014 M2 COMMUNICATIONS http://www.m2.com

Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) revealed on Thursday that it has completed target enrollment in the EffiKIR trial with 150 Acute Myeloid Leukemia (AML) patients randomised.

The company added EffiKIR is a double-blind placebo-controlled randomized Phase II trial of lirilumab as maintenance treatment in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission. The primary efficacy endpoint is leukemia-free survival. Secondary endpoints include safety and overall survival.

This trial is based on the capacity of activated Natural Killer (NK) cells to directly kill tumor cells and trigger broad immune activation. The clinical studies show that activated NK cells can significantly lower the recurrence of various hematological malignancies, including AML, following hematopoietic stem cell transplantation, said the company.

According to the company, the trial is sponsored by Innate Pharma within the context of the licencing agreement with Bristol-Myers Squibb Company (NYSE:BMY) and is performed in France, with the participation of the two French clinical cooperative groups, ALFA and GOELAMS.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jul 25, 2014
Words:201
Previous Article:GSK's RTS,S is the world's first malaria vaccine candidate to undergo EU regulatory review.
Next Article:SFW Capital Partners sheds AGDATA to Vista Equity Partners.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters